-+ 0.00%
-+ 0.00%
-+ 0.00%

BEAM THERAPEUTICS PRESENTS UPDATED CLINICAL DATA FROM THE PHASE 1/2 TRIAL OF BEAM-302 IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2026

Reuters·09/08/2026 10:00:01

Please log in to view news